Creo becomes first company to achieve demo scale production of rare cannabinoid CBGA

January 31, 2021 |

In California, Creo, an ingredient company with a proprietary platform for producing natural rare cannabinoids without the cannabis plant, has produced cannabigerol (CBG) and cannabigerolic acid (CBGA) through fermentation at 12,500-liter scale, with performance matching or exceeding expectations. Creo is the first fermentation-based cannabinoid company to successfully produce finished CBGA.

Rare cannabinoids such as CBG and CBGA (“CBG/A”) are being studied for a range of potential benefits; but they’re only found in small quantities in the plant and can be challenging to extract, making CBG/A hard to produce at scale. To enable broader access to CBG/A, Creo has partnered with biotech industry-leader Genomatica to create a patented fermentation technology platform that produces consistent high-quality, rare cannabinoids, sustainably, at scale, and at a higher purity level than traditional methods. Commercial production and supply are expected to begin in Q2 2021.

Print Friendly, PDF & Email

Tags: , , ,

Category: Fuels

Thank you for visting the Digest.